A comprehensive clinical trajectory of EGFR A763_Y764insFQEA-positive non-small cell lung cancer treated with fifth-line osimertinib following circulating tumor DNA-based detection: a case report
Year: 2025
Type: article
Study design: Case Report
Abstract: Background: -mutated non-small cell lung cancers (NSCLCs) and are generally resistant to first- and second-generation tyrosine kinase inhibitors (TKIs). Among these, the A763_Y764insFQEA variant represents a rare, structurally distinct subtype that demonstrates sensitivity to multiple EGFR-TKIs. However, clinical evidence in Asian populations remains limited. Case Description: A763_Y764insFQEA variant. Osimertinib (80 mg daily) was initiated as fifth-line therapy, achieving a partial response by two months and disease control lasting approximately five months. Treatment continued beyond radiographic progression based on clinical benefit, with an overall survival of 10 months following osimertinib initiation. Conclusions: alterations.
Institution: Saitama Red Cross Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7116752124